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The conventional glycemic indices used in management of diabetic patients includes A1c, fructosamine, 1,5-anhydroglucitol, and 
glycated albumin (GA). Among these indices, A1c is currently used as the gold standard. However, A1c cannot reflect the glyce-
mic change over a relatively short period of time, and its accuracy is known to decrease when abnormalities in hemoglobin me-
tabolism, such as anemia, coexist. When considering these weaknesses, there have been needs for finding a novel glycemic index 
for diagnosing and managing diabetes, as well as for predicting diabetic complications properly. Recently, several studies have 
suggested the potential of GA as an intermediate-term glycation index in covering the short-term effect of treatment. Further-
more, its role as a pathogenic protein affecting the worsening of diabetes and occurrence of diabetic complications is receiving 
attention as well. Therefore, in this article, we wanted to review the recent status of GA as a glycemic index and as a pathogenic 
protein. 
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INTRODUCTION
The importance of accurately assessing glycemic status in the 
management of diabetic patients cannot be overemphasized. 
Various parameters including fasting glucose level, postpran-
dial glucose level, and glycated hemoglobin are used to great 
effect in determining the glycemic status of patients, and their 
clinical significance has already been proven through numer-
ous epidemiological and clinical studies. Although these three 
glycemic indices provide useful information, in several cases 
these indices alone are inadequate. For example, appropriately 
monitoring glycated hemoglobin level is difficult in the setting 
of an abnormal hemoglobin metabolic pathway, such as ane-
mia, decreased renal function, and gestational diabetes. Fur-
thermore, since glycated hemoglobin reflects a change in gly-
cemic status over a period of 2 to 3 months, it is inappropriate 
in monitoring the therapeutic effects in earlier stages in the 
management of diabetes. Such limitations act as obstacles in 
the use of glycated hemoglobin levels in clinical settings. 
  Recently, the value of glycated albumin (GA) as a glycemic 
control marker has been validated in several studies. The half-
life of albumin is approximately 15 days, and GA level is be-
lieved to reflect the glycemic change over a 2-week period. 
Therefore, GA can be useful in evaluating the therapeutic ef-
fect of recently substituted hypoglycemic agents at an early 
stage. GA can also act as a valuable glycemic control marker in 
diabetic patients with various comorbidities since it is unrelat-
ed to the metabolism of hemoglobin. This review attempts to 
cover various aspects of GA, from basic science to clinical us-
age, in detail, along with an overview of the recent studies on 
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the subject. 
GLYCATED ALBUMIN AS AN INTERMEDIATE 
GLYCATION INDEX 
Since the United Kingdom Prospective Diabetes Study and its 
follow-up studies, as well as the Diabetes Control and Compli-
cations Trial, little controversy remains that individualized in-
tensive glucose control reduces or delays hyperglycemia-in-
duced vascular complications in diabetic subjects [1-3]. To 
achieve and maintain intensive or acceptable glucose control, 
accurate and effective glycemic indicators, with which biologi-
cal and clinical variability do not interfere, are essential. By 
overcoming many shortcomings of the methodology for mark-
ers of glucose control, glycemic indicators have contributed to 
reaching and maintaining glucose targets and thereby optimize 
glycemic control.
  Glucose or diabetes monitoring parameters can be simply 
classified into indices of protein glycation or non-protein mark-
ers. Glycated protein indices including glycated hemoglobin 
(A1c), fructosamine (FA), and GA are currently the mainstay 
method for glycemic monitoring. Glycation of proteins within 
the body, such as plasma proteins, enzymes, hormones, matrix 
proteins, membrane, and intracellular proteins, etc., correlates 
with blood glucose levels and the duration of protein exposure 
to them. Thus, the relative amount of glycated protein serves 
as an indirect record of glycemic status over the period of pro-
tein turnover. Of the glucose monitoring markers using pro-
tein glycation, A1c, is considered the gold standard in the clin-
ical setting. In addition, recent efforts addressing reference 
method standardization have empowered A1c as a diagnostic 
tool for diabetes [4]. However, the use of A1c as a glycation in-
dex faces some challenges that are not easily overcome. Because 
hemoglobin resides within erythrocytes, its glycation is affect-
ed by variant types of hemoglobin and a myriad of diseases in-
fluencing erythrocyte lifespan. Thus, A1c does not accurately 
represent glycemic control in such conditions. FA, named for 
its chemical similarity to fructose, represents the sum of all 
fructosamine residue (ketoamine) linkages resulting from gly-
cated serum proteins. Thus, it is a measurement of glycated se-
rum proteins, the most common of which is albumin [5]. Al-
though FA is not influenced by diseases characterized by ab-
normal hemoglobin metabolism, it is strongly influenced by 
the concentration of serum proteins and low-molecular-weight 
substances coexisting in the plasma (e.g., bilirubin, hemoglo-
bin, and uric acid) [6,7]. In order to overcome the drawbacks 
of FA while maintaining its advantages, the idea of using GA 
as a glycation index was developed. GA, which is theoretically 
not affected by disorders of hemoglobin metabolism or by the 
concentration of serum proteins and low-molecular-weight 
substances, is now gaining popularity as a useful glycation in-
dex for glucose monitoring. Because this method calculates 
the ratio of GA to total serum albumin, it is not influenced by 
the concentration of serum albumin [6]. Glycation of albumin 
involves a slow, non-enzymatic reaction initially involving the 
attachment of glucose or its derivatives to free amine groups of 
albumin, leading to formation of stable ketoamine [8]. Apoli-
poprotein B (Apo-B), a component of low density lipoproteins 
(LDLs), is also glycated; however, tests for glycated apo-B are 
unavailable in clinical practice. The particular interest in gly-
cated LDL lies not in its use as a glycation index for glucose 
monitoring but in its involvement in the development of ath-
erogenesis [9,10].
  The currently available non-protein markers are 1,5-anhy-
droglucitol (1,5-AG) and glucose levels in blood or serum. The 
compound 1,5-AG is a circulating polyol molecule. Under nor-
mal physiological conditions, 1,5-AG filtered from the blood 
by kidney glomeruli is entirely reabsorbed by the renal tubules. 
Because of its structural similarity to glucose, 1,5-AG must 
compete with glucose for reabsorption, leading to a decline in 
plasma 1,5-AG levels when glucose in the circulation exceeds 
approximately 180 mg/dL [11]. Thus, 1,5-AG level is not actu-
ally a measure of mean glycose level but rather a measure of 
hyperglycemic excursions [5]. Though 1,5-AG reflects post-
prandial excursions more accurately than either A1c or FA [12], 
it is not recommended for glucose monitoring of patients 
whose renal hemodynamics are unstable. Another non-pro-
tein and non-glycation index is blood or serum glucose level, 
which could be checked and calculated by timed sampling. The 
glucose variation or fluctuation can be measured in the clini-
cal setting using self-monitoring of blood glucose or a contin-
uous glucose monitoring system. In addition, standard devia-
tion, continuous overlapping net glycemic action, mean am-
plitude of glycemic excursion, and mean of the daily differenc-
es are also calculated for the assessment of glycemic variability 
for academic purpose [13,14].
  Glycemic indices may also be classified as long-, intermedi-
ate-, or short-term glycemic indicators. The utility of A1c as a 
long-term glycemic indicator resides in the long half-life of 
erythrocytes (approximately 120 days). Consequently, A1c re-100
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flects glycemic status over the past 2 to 3 months. For interme-
diate-term glycemic indices, glycated serum proteins and al-
bumin were introduced to assess glycemic status over inter-
mediate periods (2 to 4 weeks) that reflect the half-lives of the 
respective molecules in the serum. GA, with a half-life of 12 to 
19 days, would be an excellent glycation index of recent ambi-
ent glycemia [15]. Together, GA and FA levels may act as a pow-
erful monthly management tool for diabetes. The indices 1,5-
AG and glycated apo-B could serve as short-term glycemic in-
dicators. Due to the short circulating half-life of LDLs (approx-
imately 3 to 5 days), glycated LDL level reflects mean glycemia 
over approximately the preceding week [9]. The shortest index 
may be 1,5-AG. Because of the competitive inhibition of 1,5-AG 
reabsorption in the kidney tubule by glucose, 1,5-AG levels in 
the blood may respond with high sensitivity within 24 hours 
[11], reflecting even transient elevation of glucose within a few 
days [12]. Stettler et al. [16], however, suggested that the prac-
tical utility of 1,5-AG lies in its strong association with 2-hour 
postprandial glucose values in the preceding 2 weeks. From 
the perspective of quality of glucose control, another use of 
1,5-AG in conjunction with A1c was in patients with moder-
ate or good glucose control [12]. However, a study on the rela-
tionships between continuous glucose monitoring system data 
and the glycemic indices reported that GA levels more strong-
ly correlate with plasma glucose levels and the glucose fluctua-
tion index than those of A1c or 1,5-AG, especially in subjects 
with poor glucose control [17].
ALBUMIN AND ITS ANTIOXIDANT 
ACTIVITIES IN PLASMA
Albumin, synthesized mainly in the liver, is the most abundant 
of the plasma proteins, representing more than 80% of the to-
tal molecules and 50% to 60% of the total protein in the plasma 
of normal, healthy individuals [18]. Structurally, albumin is 
made up of 585 amino acids and contains 35 important cyste-
ine residues that, except for Cys-34, form disulfide bridges that 
contribute to the overall tertiary structure of the protein (Fig. 1). 
Functionally, it exerts a wide variety of physiological and phar-
macological functions, including regulation of colloid osmotic 
pressure of plasma due to its low molecular weight (67 kDa); 
transportation of hormones, fatty acids, drugs and metabolites 
due to its tertiary structure; and regulation of microvascular 
permeability, antioxidant activity, anti-thrombotic activity, and 
anti-inflammatory activity [10,19]. 
  The antioxidant role of albumin has been underappreciated 
in diabetes. In general, a large proportion of the antioxidant 
properties of total serum can be attributed to albumin [20]. 
Bourdon and Blache [21] have shown that more than 70% of 
the free radical-trapping activity of serum, as assayed using the 
free radical-induced hemolysis test, was due to human serum 
albumin. In sites of inflammation, augmented albumin con-
centrations have been found to exert potent antioxidant activi-
ty [22]. Thus, human serum albumin is beneficial in patients 
with a variety of disorders by limiting oxidative damage. The 
antioxidant properties of albumin mainly arise from limiting 
reactive oxygen species (ROS) production by ligand-binding 
capacities as well as scavenging ROS through free radical-trap-
ping activity. Regarding ligand-binding capacities, albumin 
easily binds molecules, such as metals ions, fatty acids, etc. Free 
Cu(II) and Fe(II) are metal ions that are very potent generators 
of ROS upon reacting with oxygen. They also interact with hy-
drogen peroxide, leading to formation of the deleterious hy-
droxyl radical via the Fenton reaction. When bound to albu-
min, copper and iron are less likely to be involved in the Fen-
ton reaction [20]. The predominant contribution of albumin 
as an antioxidant in plasma might be due to several residues 
with antioxidant activities. As previously described, albumin 
consists of 585 amino acids and contains 6 methionine (Met) 
residues and 35 cysteine (Cys) residues. Of the 35 cysteine res-
idue sites in albumin, Cys-34 is the only free cysteine residue 
not involved in disulfide bond formation, which endows albu-
Fig. 1.  Structure of albumin.
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min with its potent antioxidant activity. In reduced form, Cys-
34 is able to not only scavenge hydroxyl radicals [23] but also 
covalently bind drugs [24]. Because of the abundance of albu-
min in plasma, a single reduced Cys-34 is enough to form the 
largest pool of thiols in the blood, contributing to powerful 
antioxidant effects. Six Met residues in human albumin repre-
sent an oxidation-sensitive amino acid. Levine et al. [25] sug-
gested that the oxidation and reduction cycle of Met residues 
could serve as a ROS scavenging system to protect proteins 
from extensive modification.
GLYCATION: EARLY AMADORI PRODUCTS 
AND ADVANCED GLYCATION END 
PRODUCTS
It is inevitable for proteins and lipids in the body to be exposed 
to hyperglycemia-related altering factors or reactions, whether 
enzymatic or non-enzymatic. Glycation and oxidation are the 
most common major non-enzymatic mechanisms. Glycation 
(sometimes called non-enzymatic glycosylation) is a simple 
process whereby excess sugar molecules, such as fructose or 
glucose, attach themselves to otherwise normal protein or lip-
id molecules in the blood without enzymatic intervention [26]. 
Monosaccharides inherently possess different glycation activi-
ties; it is known that galactose and fructose have approximate-
ly 10 times the glycation activity of glucose [27]. Concerns 
about glycation in diabetes arise from the fact that a reducing 
sugar has the potential to induce the glycation and impair the 
function of several proteins. Because all proteins are vulnera-
ble to glycation, this impairment may have profound effects. 
Products of glycation can be classified into early or advanced 
products. Initially, a reversible, unstable Schiff base is formed 
from the attachment of glucose or derivatives with free amine 
groups of albumin (reversible glycation, 1 to 2 weeks of glyca-
tion; Fig. 2A and B), leading to formation of a stable fructos-
amine residue (ketoamine) through the removal of water (Fig. 
2C). Rearrangement of this compound finally yields the irre-
versible Amadori compound (irreversible glycation, 6 to 8 
weeks of glycation) (Fig. 2D) [28-30]. This is the early glyca-
tion process and is also known as the Maillard reaction. Ad-
vanced modifications in these early stage glycation products 
(Amadori adducts), such as rearrangement, oxidation, polym-
erization, and cleavage give rise to irreversible conjugates, 
called advanced glycation end products (AGE) [31]. 
CLINICAL IMPLICATIONS OF GLYCATED 
ALBUMIN 
Glycemic indicator for intermediate-term glycemic control
Although GA testing may initially be viewed as an adjunct to 
A1c in the management of diabetes, its immediate applications 
are apparent as monthly tool for diabetes management. GA of-
fers a similar reference discrepancy as A1c with a half-life on 
the order of 3 weeks rather than the 3 to 4 months of A1c. It 
also allows physicians to achieve better glycemic control and 
finally results in a superior index to use for reducing diabetic 
micro- and macrovascular complications. Amidst the ongoing 
debates about the interpretation of A1c, there is no consensus 
on a suitable cutoff value for A1c across different racial or eth-
nic populations. In a recent study on racial differences in gly-
cemic markers, Selvin et al. [32] indicated that differences be-
tween African-American and Caucasian population with re-
spect to GA, FA, and 1,5-AG levels parallel the differences in 
A1c among both non-diabetic and diabetic subjects. This re-
sult might imply a similarity between GA and A1c on racial 
and ethnic differences. 
  GA is now gaining popularity as an index of glycemic con-
trol during intensive treatment [33]. Won et al. [34] recently 
showed a significant direct correlation between changes in GA 
over a 3-week period and those in A1c over a 3-month period 
after intensified substitution of anti-diabetic drugs (oral hypo-
glycemic agent-based [r=0.735, P<0.01] and insulin-based 
[r=0.778, P<0.01]). A prospective, randomized, controlled 
Fig. 2.  Glycation process of albumin.
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trial has shown that initiation of once-daily basal insulin or bi-
phasic insulin analogue followed by an intensified twice-daily 
biphasic insulin analogue for non-respondent subjects with 
greater than 20% GA at 3 weeks after the initiation of therapy 
yielded a significantly higher A1c reduction with guidance of 
interim GA values [35]. Thus, the use of GA as an intermedi-
ate-term index contributed in a guiding role to the control of 
glycemia. In addition, if the proper management of gestational 
diabetes or type 1 or 2 diabetes during pregnancy was found 
to be monthly diabetes management, GA could act as a stan-
dard glycation index. Thus, well-designed clinical studies for 
subjects with gestational diabetes are needed to determine the 
optimal glucose monitoring interval benefiting pregnant sub-
jects and their offspring.
  Even after proof of concept that intermediate-term glycemic 
indicators are beneficial and effective in achieving better gly-
cemic control, leading to reduced diabetic complications 
through guiding glucose control, questions could be raised 
about which kind of glycemic marker would best satisfy the 
aforementioned unmet needs. As described previously, FA has 
physiologic disadvantages in that its levels are strongly influ-
enced by the concentration of serum proteins and low-molec-
ular-weight substances coexisting in the plasma [6,7]. FA has 
been scrutinized by the Food and Drug Administration in the 
United States, and a few clinical studies with mixed results 
were reported [36]. These clinical and practical data have led 
to its flagging popularity recently. During pregnancy, 1,5-AG 
is not a suitable parameter for glycemia management due to 
unstable renal hemodynamics [36].
Recommended diabetes and pathologic conditions for GA 
measurements
Several studies have reported discrepancies in A1c as a stan-
dard indicator for glycemic control in patients with diabetes-
associated pathologies. The diseases and pathological condi-
tions in which GA is a more accurate glycation index might be 
diabetic subjects with hemolytic anemia, end-stage renal dis-
ease (ESRD), and iron deficiency. GA may also be more accu-
rate for diabetic subjects during pregnancy [6,10,33,36]. Of 
the numerous pathologic conditions, studies targeting diabetic 
patients with ESRD have been well-designed and frequently 
conducted. Because of an altered erythrocyte lifespan caused 
by renal anemia, A1c measurements are low with respect to 
glycemic status in patients with ESRD. These findings issued 
concerns that physicians may underestimate and under-treat 
hyperglycemia in patients with chronic renal failure [36]. There 
is, however, no relevant evidence established by randomized 
controlled studies demonstrating that GA is better in prevent-
ing morbidity and mortality than A1c in this high-risk diabet-
ic population. Though there is a lack of studies of abnormal al-
bumin homeostasis in patients with ESRD, it is not difficult to 
imagine that there are potential fluctuations in GA in this pop-
ulation. In these regards, Mehrotra et al. [37] stated that it might 
be more reasonable to solve this drawback by obtaining con-
sensus on different cutoffs for A1c in subjects with end-stage 
renal disease. 
  In contrast to A1c, GA itself is strongly involved in the de-
velopment of major diabetic complications, including arterial 
stiffening, peripheral vascular calcification, nephropathy, reti-
nopathy, and Alzheimer’s disease [10]. Notwithstanding these 
merits, two important questions need to be answered through 
further prospective studies for GA to be considered a standard 
glycation index in these populations. First, evidence that chang-
es in GA show better association with time-dependent pro-
portional morbidities and mortality than those of A1c is re-
quired. Second, quarterly GA measurements need to assist 
physicians in achieving and maintaining better glycemic con-
trol and result in reducing diabetic complications in these 
populations. 
Influential variable affecting GA/A1c ratio
Despite a very strong relationship between A1c and GA, some 
large discrepancies between the two values exist under certain 
physiologic and pathologic conditions. Because A1c and GA 
levels are dependent on the lifespan of erythrocytes and half-
life of serum albumin, respectively, variability in the lifespan 
of erythrocytes and half-life of albumin between individuals 
could account for some unexplained GA/A1c ratio [38]. Physi-
ologically, the rate of the nonenzymatic-glycation process on 
protein in vivo is approximately nine times faster than that of 
human hemoglobin [39], resulting in a ten-fold greater glyca-
tion reaction speed in albumin than in hemoglobin [40]. The 
conventional conversion of GA levels to A1c levels is often 
performed using the relationship A1c=GA/3, which is empir-
ical and has a statistical basis [38]. Clinical reports in Korea 
and Japan have shown a wide range of mean ratios of GA to 
A1c (from 2.0 to 4.0) [34,38,41-44]. These differences in mean 
ratios of GA to A1c may originate from the heterogeneity of 
the study population, especially for A1c levels and stable or 
unstable status of glucose excursions. The mean GA/A1c ratio 103
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of those who participated in a periodic health examination who 
were mostly free of diabetes was 2.68 [42]. However, in studies 
targeting type 2 diabetics, including those with unstably con-
trolled A1c with >0.5% fluctuation in A1c across 6 months, 
serum GA levels increased by 3% to 4% for every 1% increase 
in serum A1c levels [33,38]. Therefore, that GA/A1c ratio in-
creased along with higher A1c may be attributable to more 
marked increases in GA levels than A1c levels in subjects with 
poorly controlled diabetes. Even among similar A1c levels, GA 
better reflected postprandial hyperglycemia [6,33,45], which is 
mainly caused by inadequate or dysfunctional endogenous in-
sulin secretion. Koga et al. [41] measured GA and A1c in type 
1 and 2 diabetes and found that the GA/A1c ratio was signifi-
cantly higher in type 1 diabetic patients, in which glucose lev-
els fluctuate over wider ranges, than in type 2 diabetic patients. 
Furthermore, Kim et al. [44] demonstrated that insulin secre-
tory functions, such as HOMA-β and insulinogenic index, but 
not insulin resistance, associates with the ratio of GA to A1c in 
type 2 diabetics. The ratio of GA to A1c is increased as insulin 
secretory function is diminished. The reason behind these 
findings may lie in that fact that postprandial insulin secretory 
dysfunction in response to meal loading causes postprandial 
hyperglycemia, which directly leads to an augmented GA/A1c 
ratio. In a clinical view of this phenomenon, a physician could 
interpret the higher GA/A1c ratio as a greater postprandial 
glucose fluctuation due to deteriorating insulin secretory func-
tion. By assessing the meaning of the GA/A1c ratio, physicians 
may clinically relate the relevance of the higher ratio in situa-
tions of similar mean glucose levels. Because elevated levels of 
GA induce irreversible vascular damage in diabetes mellitus, 
further studies on the clinical relevance of higher GA/A1c ra-
tios on diabetic complications would satisfy the unmet need of 
biologic impact of GA on cell pathophysiology. Thus, serial re-
sults guide its usefulness for management of these patients in 
clinical settings.
  However, some physiological variables, such as body mass 
index or age, could affect GA levels. Also, in certain pathologic 
conditions affecting albumin metabolism, such as thyroid dys-
function, nephrotic syndrome, or liver cirrhosis, the ratio of 
GA to A1c should be interpreted with caution [10,46]. We 
summarized the clinical implication of GA/A1c (Table 1). 
Glycated albumin measurement to diagnose diabetes 
mellitus 
Despite the potential benefits of GA, on the lack of normal ref-
erence data on GA might limit its use as a diagnostic tool for 
diabetes. In contrast to A1c, GA levels are not influenced by 
sex [42,47]. In 2006, only the Japan Diabetes Society reported 
the reference intervals of GA (12.3% to 16.9%) in a normal 
population [42]. Recently, Hiramatsu et al. [48] reported refer-
ence intervals of GA in 676 healthy Japanese pregnant women 
of 11.5% to 15.7%. Furusyo et al. [42] measured fasting plasma 
glucose, A1c, and GA in 1,575 mostly non-diabetic Japanese 
subjects. Using receiver operating characteristic curve (ROC) 
analysis, GA ≥15.5% was optimal for predicting diabetes with 
a sensitivity of 83.3% and a specificity of 83.3%. Another Chi-
nese study enrolled 1,971 outpatient subjects who underwent 
a 75 g oral glucose tolerance test and GA measurement and 
found a GA value of 17.1% to be an optimal cutoff in Chinese 
subjects using ROC analysis with 76.82% sensitivity and 76.89% 
specificity for the diagnosis of diabetes [49].
  As previously described, GA is a more accurate glycation 
index to control glucose in certain diabetes-associated condi-
tions, and further studies should be directed to assess the opti-
mal cutoff value and clinical relevance in diabetic subjects with 
hemolytic anemia, ESRD, iron deficiency, and pregnancy.
Glycated albumin as a pathogenic protein
In understanding the biologic impact of GA on diabetes and 
its complications, one should bear in mind that GA is a pre-
cursor of AGEs [50]. As previously described, high levels of 
glucose induce non-enzymatic glycation reactions between 
glucose and derivatives with free amine groups of albumin. 
These reactions successively produce a reversible unstable 
Schiff base, a stable fructosamine residue (ketoamine), an irre-
versible Amadori compound, and ultimately irreversible con-
jugates, called AGEs. Elevated levels of GA and AGEs are 
known to be actively involved in the development of diabetic 
vascular complications, such as retinopathy, nephropathy, 
neuropathy, and coronary artery disease [50-53]. Because of 
the approximately 17-day half-life of GA, GA may not reach 
the total levels of AGEs. However, GA is directly associated 
with the production of ROS, resulting in cell injury. Experi-
mental endothelial cell damage due to ROS showed high clini-
cal relevance in severity and extent of coronary artery disease 
and arterial stiffening in hemodialysis patients with type 2 dia-
betes [50,54,55].
  To accept that GA is a pathogenic protein, one must also 
keep in mind that albumin contributes a large proportion of 
the antioxidant activity of total serum [20]. The antioxidant ef-104
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fects of albumin are due to limiting ROS production and scav-
enging ROS, as described previously. Glycation-induced mod-
ifications have a considerable impact on albumin functional 
properties, which can be related to alterations of its conforma-
tion [10,56]. Moreover, the sole residues prone to glycation in 
albumin are lysine, arginine, and cysteine, which is attributed 
to their highly nucleophilic characteristics [10]. Thus, glycation 
may block the powerful antioxidant properties of the Cys-34 
residue. In addition, glycation is usually associated with oxida-
tive modifications, which affect early stage glycation products. 
The simultaneous or combined reaction of oxidation during 
glycation is termed glycoxidation [10,57]. This oxidative state 
has been revealed through both an increase in carbonylated 
protein levels and a decrease in the reduced state of Cys-34 
[10,58,59]. Therefore, the glycation of albumin brings about 
impaired antioxidant capacities partly via losing the free sul-
phydryl group of Cys-34 and partly via the pathologic effects 
of glycoxidation itself on endothelial and mesangial cells and 
macrophages. Furthermore, GA suppresses glucose-induced 
insulin secretion, impairing glucose metabolism in rat pancre-
atic β-cells [60]. These findings support and explain the strong 
involvement of GA in the development of major diabetic com-
Table 1.  Literature review of clinical implication of GA/A1c ratio
No. Patients No. of patients Interpretation Reference
1 T2DM T2DM: 142 The GA/HbA1c ratio was significantly higher when  
patients were in hyperglycemic than when glycemic 
control was good 
Endocr J 2007;54:139-44 [43]
2 T2DM T2DM: 222 Serum bioavailable testosterone concentration correlat-
ed negatively with the ratio of GA to A1c in men with 
type 2 diabetes, which may lead to underestimation of 
A1c in hypogonadal men with type 2 diabetes.
Diabetes Care 2008;31:397-
401
3 T1DM&T2DM T1DM: 93
T2DM: 75
The ratio of GA levels to HbA1c levels was significantly 
higher in type 1 diabetes than that in type 2 diabetes.
Endocr J 2008;55:503-7
4 T2DM patients with 
liver disease
Liver disease: 259
T2DM: 829
These results suggest that GA/A1c ratio could be an use-
ful marker for different diagnosis when facing patients 
with abnormal serum ALT level in a clinical setting.
Rinsho Byori 2008;56:761-6
5 Gastrectomized  
patients with  
diabetes 
Control: 87
Gastrectomy: 62
The BMI-adjusted GA/HbA1c ratio was also significant-
ly higher in the gastrectomized subjects than in the 
control subjects.
Ann Clin Biochem 
2010;47(Pt 1):39-43 [45]
6 T2DM T2DM: 202 In diabetic patients with decreased insulin secretion,  
serum GA levels are higher relative to A1c.
Diabetes Care 2010;33:270-2 
[41]
7 Pregnant  
diabetic women 
Pregnant diabetic  
patients: 17
GA/A1c ratio was significantly decreased in late  
pregnancy
Diabetes Care 2010;33:509-
11
8 T1DM&T2DM T1DM: 35
T2DM: 42
Fulminant T1DM can be distinguished from untreated 
T2DM by GA/HbA1c ratio at initial visit before  
treatment for diabetes
Ann Clin Biochem 
2010;47(Pt 4):313-7
9 T1DM patients with 
smoking
T1DM: 81 GA/HbA1c ratio in smokers was significantly lower than 
that in nonsmokers 
Med Princ Pract 
2010;19:415-7
10 T2DM  T2DM: 202 There was an inverse correlation between Hb levels and 
GA/HbA1c ratio 
Clin Chim Acta 
2011;412:253-7
11 T2DM T2DM: 1,038 The GA/A1c ratio tended to increase as A1c increased. 
Postprandial glucose and body mass index affected the 
GA/A1c ratio.
Acta Diabetol 2011;48:167-
72  [33]
12 T2DM  T2DM: 758 The GA/A1c ratio is significantly correlated with insulin 
secretory function but not with insulin resistance.
Clin Endocrinol (Oxf)  
E-pub 2011 Dec 9 [44]
13 T2DM patients with 
chronic kidney  
disease
T2DM: 25 The GA/HbA1c ratio was significantly higher in diabetic 
patients with chronic kidney disease compared with 
controls
Nephrology (Carlton) 
2012;17:182-8
GA, glycated albumin; T1DM, type 1 diabetes; T2DM, type 2 diabetes; ALT, alanine aminotransferase; BMI, body mass index.105
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plications and the identification of people at risk for microvas-
cular conditions.
CONCLUSIONS
Initially, the utility of GA was viewed as an adjunct to A1c for 
diabetes management but is now gaining popularity in month-
based management of diabetes and diabetes-associated pa-
thologies, such as hemolytic anemia, ESRD, and iron deficien-
cy, as well as pregnancy. In addition, albumin is a pivotal anti-
oxidant in human serum. Therefore, glycation and accompa-
nied oxidation of albumin leads to a loss of antioxidant activity 
and generates an atherogenic protein in diabetes. This could 
explain why higher level GA related with vascular complication 
and diminished insulin secretory function. In conclusion, GA 
appears to have potential as a glycation index in diagnosing 
diabetes, guiding parameters after intensified medication, eval-
uating insulin secretory dysfunction along with glucose chang-
es and predictor of diabetic complications. 
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